 |
|
|
43rd Annual Meeting
American Society of Clinical Oncology
June 1 - 5, 2007 | Chicago, Illinois
|
 |
|
Highlights from ASCO 2007
The results of more than 4,000 cancer research studies are being presented at the 43rd annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, from June 1-5, 2007. Nearly 25,000 cancer specialists from around the world are gathering to discuss the latest advances in cancer care, treatment, and prevention.
|
|
Less-Intense Chemo Effective in Children with Intermediate-Risk Neuroblastoma
(Posted: 06/13/2007) - Infants and children with intermediate-risk neuroblastoma who received a less-intensive chemotherapy regimen had three-year overall survival rates as good as those patients in an earlier trial who received treatment that was more intensive and more toxic, according to findings presented at the 2007 ASCO meeting in Chicago.
Radiotherapy Can Prevent Spread of Small-Cell Lung Cancer to the Brain
(Posted: 06/20/2007, Reviewed: 08/21/2007) - Radiation therapy to the head, given to patients who had responded to chemotherapy for advanced small-cell lung cancer, reduced by about two-thirds the risk that patients' tumors would spread to the brain, according to findings presented at the 2007 ASCO meeting in Chicago.
Cetuximab (Erbitux®) Plus Chemo Extends Survival in Advanced Head and Neck Cancer
(Posted: 06/26/2007, Reviewed: 09/16/2008) - Patients with recurrent or metastatic squamous cell carcinoma of the head and neck who received cetuximab (Erbitux®) in addition to standard chemotherapy lived about three months longer than those receiving chemotherapy alone, according to findings presented at the 2007 ASCO meeting in Chicago.
Gabapentin Helps Hot Flashes From Prostate Cancer Treatment
(Posted: 06/20/2007) - The drug gabapentin (Neurontin®) effectively reduced the intensity and duration of hot flashes in a clinical trial of more than 200 men receiving hormonal treatment for their prostate cancer, according to findings presented at the 2007 ASCO meeting in Chicago.
Chemotherapy Before Surgery May Increase Survival in Stomach Cancer
(Posted: 07/09/2007) - Chemotherapy given before surgery for cancer of the lower esophagus and stomach increased the number of patients surviving for five years compared to surgery alone, according to findings presented at the 2007 ASCO meeting in Chicago.
Sorafenib for Advanced Liver Cancer Increases Survival
(Posted: 06/13/2007, Reviewed: 07/30/2008) - The targeted drug sorafenib (Nexavar®) has improved the survival of patients with advanced liver cancer, according to the July 24, 2008, New England Journal of Medicine.
Bevacizumab (Avastin®) Benefits Some Patients With Advanced Kidney Cancer
(Posted: 06/20/2007, Reviewed: 01/22/2008) - Addition of the targeted drug bevacizumab (Avastin®) to interferon alpha staved off disease progression for significantly longer than a placebo in patients with advanced kidney cancer, according to findings presented at the 2007 ASCO meeting in Chicago.
Heart Problems From Trastuzumab (Herceptin®) Do Not Increase in the Short Term
(Posted: 06/25/2007) - Women with breast cancer who take the drug trastuzumab (Herceptin®) are at risk of heart problems during treatment. Now a study has shown that the incidence of such problems does not increase in the short term, though the long-term effects remain unknown, according to findings presented at the 2007 ASCO meeting in Chicago.
Imatinib (Gleevec®) Reduces Cancer Recurrence in Patients with Surgically Removed GIST
(Posted: 06/25/2007) - Patients with localized gastrointestinal stromal tumors (GIST) who took imatinib (Gleevec®) after surgical removal of the primary tumor were less likely to have a recurrence of their cancer, according to findings presented at the 2007 ASCO meeting in Chicago.
Heat Therapy Makes High-Risk Soft Tissue Sarcomas More Treatable
(Posted: 07/09/2007) - Patients with high-risk soft tissue sarcomas whose tumors were treated with a kind of localized heat therapy in addition to receiving other treatment lived longer without their disease worsening or returning, according to findings presented at the 2007 ASCO meeting in Chicago.
|
|
|
